JP2023537477A5 - - Google Patents
Info
- Publication number
- JP2023537477A5 JP2023537477A5 JP2023507267A JP2023507267A JP2023537477A5 JP 2023537477 A5 JP2023537477 A5 JP 2023537477A5 JP 2023507267 A JP2023507267 A JP 2023507267A JP 2023507267 A JP2023507267 A JP 2023507267A JP 2023537477 A5 JP2023537477 A5 JP 2023537477A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- use according
- lymphoma
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060413P | 2020-08-03 | 2020-08-03 | |
| US63/060,413 | 2020-08-03 | ||
| US202063115312P | 2020-11-18 | 2020-11-18 | |
| US63/115,312 | 2020-11-18 | ||
| PCT/US2021/030192 WO2022031330A1 (en) | 2020-08-03 | 2021-04-30 | Compositions and methods for treating diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537477A JP2023537477A (ja) | 2023-09-01 |
| JP2023537477A5 true JP2023537477A5 (enExample) | 2024-05-15 |
Family
ID=80117618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507267A Pending JP2023537477A (ja) | 2020-08-03 | 2021-04-30 | 疾患及び障害を治療するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230310444A1 (enExample) |
| EP (1) | EP4188368A4 (enExample) |
| JP (1) | JP2023537477A (enExample) |
| KR (1) | KR20230048358A (enExample) |
| CN (1) | CN116419752A (enExample) |
| AU (1) | AU2021321350A1 (enExample) |
| BR (1) | BR112023001861A2 (enExample) |
| CA (1) | CA3188171A1 (enExample) |
| CU (1) | CU20230009A7 (enExample) |
| IL (1) | IL300310A (enExample) |
| MX (1) | MX2023001296A (enExample) |
| WO (1) | WO2022031330A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| WO2023172640A1 (en) * | 2022-03-08 | 2023-09-14 | X4 Pharmaceuticals, Inc. | Treatments for single-mutant waldenström's macroglobulinemia |
| JP2025516501A (ja) * | 2022-05-11 | 2025-05-30 | キュリス，インコーポレイテッド | Ｉｒａｋ４修飾化合物による疾患及び障害の治療 |
| WO2024027750A1 (en) * | 2022-08-02 | 2024-02-08 | Beigene Switzerland Gmbh | Methods of treating pulmonary hypertension using btk inhibitors |
| WO2025208000A1 (en) * | 2024-03-29 | 2025-10-02 | Curis, Inc. | Methods of treating cancer in patients with altered protein expression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) * | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| TW201701879A (zh) * | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| US20170035881A1 (en) * | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
| EP3600270B1 (en) * | 2017-03-31 | 2023-06-14 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| HUE067356T2 (hu) * | 2017-10-31 | 2024-10-28 | Curis Inc | IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra |
| EP3800188A1 (en) * | 2019-10-02 | 2021-04-07 | Bayer AG | Substituted pyrazolopyrimidines as irak4 inhibitors |
| MX2023005591A (es) * | 2020-11-18 | 2023-05-29 | Curis Inc | Metodos de tratamiento de enfermedades y trastornos. |
| EP4319750A4 (en) * | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
-
2021
- 2021-04-30 IL IL300310A patent/IL300310A/en unknown
- 2021-04-30 CA CA3188171A patent/CA3188171A1/en active Pending
- 2021-04-30 BR BR112023001861A patent/BR112023001861A2/pt unknown
- 2021-04-30 CN CN202180057734.1A patent/CN116419752A/zh active Pending
- 2021-04-30 JP JP2023507267A patent/JP2023537477A/ja active Pending
- 2021-04-30 KR KR1020237007466A patent/KR20230048358A/ko active Pending
- 2021-04-30 CU CU2023000009A patent/CU20230009A7/es unknown
- 2021-04-30 EP EP21852519.4A patent/EP4188368A4/en active Pending
- 2021-04-30 AU AU2021321350A patent/AU2021321350A1/en active Pending
- 2021-04-30 MX MX2023001296A patent/MX2023001296A/es unknown
- 2021-04-30 WO PCT/US2021/030192 patent/WO2022031330A1/en not_active Ceased
- 2021-04-30 US US18/019,400 patent/US20230310444A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537477A5 (enExample) | ||
| AU2018236826B2 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| TWI705964B (zh) | 類鐸受體調節劑化合物 | |
| JP7187308B2 (ja) | Ｄｎａ損傷剤とａｔｒ阻害剤との組み合わせを使用する、がんを処置するための方法 | |
| US10800775B2 (en) | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same | |
| CN107873032B (zh) | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 | |
| ES2715507T3 (es) | Derivados de quinazolina usados para tratar el VIH | |
| ES2926068T3 (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
| JP5860197B1 (ja) | ウイルス感染症を処置するための治療用化合物 | |
| ES2962291T3 (es) | Formas cristalinas de (2R,5S,13aR)-8-hidroxi-7,9-dioxo-n-(2,4,6-trifluorobenzilo)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepina-10-carboxamida | |
| ES2968700T3 (es) | Diaminocarboxamida y diaminocarbonitrilo pirimidinas sustituidas, composiciones de las mismas y métodos de tratamiento con las mismas | |
| USRE49338E1 (en) | Phthalazinone derivatives and manufacturing process thereof | |
| CA2950307A1 (en) | Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate | |
| JP2023550739A5 (enExample) | ||
| CN110248951A (zh) | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 | |
| CN111848643A (zh) | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 | |
| CA3077383A1 (en) | Substituted pyrimidine piperazine compound and use thereof | |
| WO2024254602A1 (en) | Oxazolopyridin-7(4h)-one wrn inhibitors | |
| US20230017597A1 (en) | 8-substituted styryl xanthine derivatives and uses thereof | |
| WO2016049595A1 (en) | Heteroaryl inhibitors of pde4 | |
| JP7152784B2 (ja) | 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤 | |
| US20220048918A1 (en) | Pkc inhibitor solid state forms | |
| HK40106666A (en) | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide | |
| HK40042000B (zh) | 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法 | |
| EP4719606A2 (en) | Gcn2 and perk kinase modulators and methods of use thereof |